Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Colloquium supported by Celgene - Pancreatic cancer: Can better understanding of biology improve resectability and survival?

What are the biological reasons for treatment resistance in pancreatic adenocarcinoma?

Date

30 Sep 2019

Session

ESMO Colloquium supported by Celgene - Pancreatic cancer: Can better understanding of biology improve resectability and survival?

Topics

Clinical Research;  Targeted Therapy;  Cancer Biology;  Translational Research;  Pathology/Molecular Biology

Tumour Site

Pancreatic Adenocarcinoma

Presenters

David Chang

Authors

D. Chang

Author affiliations

  • Beatson Institute for Cancer Research, G61 1BD - Glasgow/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.